Brigette Roberts
CEO, Principal Executive Officer & DirectorDr. Brigette Roberts, M.D., is CEO & Principal Executive Officer of IRulya Therapeutics Inc. (formerly known as Quince Therapeutics, Inc.) from October 8, 2026 serves as its Director since May 18, 2026 and was Chief Corporate Affairs Officer since May 18, 2026 until October 8, 2026. Dr. Roberts serves as Chief Executive Officer at AI Therapeutics, Inc. She was a Healthcare Analyst at Third Point LLC. She joined AI Therapeutics after serving as an Entrepreneur in Residence at Fortress Biotech. Prior to AI Therapeutics, Inc., she was in healthcare investing as a portfolio manager at hedge funds including Third Point, CDP Capital, Angel Lane Principal Strategies, DKR Capital and her own hedge fund, YYC Capital. Prior to January 2005, she ran a healthcare portfolio at DKR Capital from 2003 to 2004 and previously worked as an Associate Healthcare Analyst at Sturza's Medical Research in 2002 and Thomas Weisel Partners in 2001. She was Board Member at Ligand Pharmaceuticals. Dr. Roberts was a Director of Ligand Pharmaceuticals Inc., since December 8, 2005. She graduated from Harvard University with a B.A. in Physics and Chemistry. Dr. Roberts then attended NYU Medical School, where she graduated with an M.D. and completed one year of general surgical residency.
Positions
- Company NameIRulya Therapeutics Inc.Stock CodeIRLAPositionCEO, Principal Executive Officer & DirectorColleagues
- JCJohn C. MilitelloCFO, Principal Financial Officer & Principal Accounting Officer
- KRKeith R. FandrickChief Operating Officer
- GRGuenter R. JanhoferChief Scientific Officer
- PBPaul B. YuChairman of Scientific Advisory Board
- LDLeone D. PattersonDirector
- JPJames P. ValentineDirector
- MBMark BrodyMember of Clinical Advisory Board
